Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Peripheral Blood Stem Cell Transplantation 85fludarabine phosphate 81Filgrastim 78Methotrexate 69Etoposide 68Cytarabine 62Rituximab 61Radiotherapy 56Cyclosporine 52Mycophenolic Acid 51Vincristine 50Whole-Body Irradiation 48Busulfan 46Tacrolimus 41Antilymphocyte Serum 40Melphalan 39Dexamethasone 39Prednisone 36Methylprednisolone 35Doxorubicin 35fludarabine 28Granulocyte Colony-Stimulating Factor 25Calcium Dobesilate 25merphos 24Leucovorin 23Cord Blood Stem Cell Transplantation 22sargramostim 18dexamethasone acetate 18dexamethasone 21-phosphate 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × CVAD protocol × Other hematologic neoplasm × Clear all
NCT01184885 2025-05-04

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Thomas Jefferson University

Phase EARLY_PHASE1 Completed
7 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡